Clinical Trial Update: Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Lebrikizumab (LY3650150) in moderate to severe atopic dermatitis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-09-16